Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Groupama Asset Managment

Groupama Asset Managment trimmed its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 1.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 400,000 shares of the biotechnology company’s stock after selling 4,000 shares during the period. Groupama Asset Managment owned 0.66% of Ascendis Pharma A/S worth $55,068,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ASND. Rice Hall James & Associates LLC grew its position in shares of Ascendis Pharma A/S by 2.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company’s stock valued at $22,562,000 after buying an additional 3,274 shares during the last quarter. Nomura Asset Management Co. Ltd. boosted its stake in Ascendis Pharma A/S by 42.5% in the third quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock valued at $2,688,000 after acquiring an additional 5,371 shares during the period. Maven Securities LTD bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at approximately $7,466,000. Exome Asset Management LLC grew its holdings in shares of Ascendis Pharma A/S by 119.2% during the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company’s stock valued at $6,547,000 after purchasing an additional 23,849 shares during the last quarter. Finally, abrdn plc raised its position in shares of Ascendis Pharma A/S by 18.3% during the 4th quarter. abrdn plc now owns 187,180 shares of the biotechnology company’s stock worth $25,769,000 after purchasing an additional 28,967 shares during the period.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $155.86 on Tuesday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The firm has a market cap of $9.46 billion, a P/E ratio of -21.95 and a beta of 0.62. The stock has a fifty day moving average price of $144.72 and a two-hundred day moving average price of $137.63.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ASND has been the subject of a number of recent research reports. UBS Group started coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective for the company. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 18th. The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Finally, Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $204.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.